Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response

BACKGROUND: One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports. METHODS: A retrospective datab...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Sarcoma Res
Auteurs principaux: Libertini, M., Mitra, I., van der Graaf, W. T. A., Miah, A. B., Judson, I., Jones, R. L., Thomas, K., Moskovic, E., Szucs, Z., Benson, C., Messiou, C.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950191/
https://ncbi.nlm.nih.gov/pubmed/29785261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-018-0100-3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires